BCT-521

**BCT-521** is an orally administered fixed-dose small-molecule cannabinoid combination containing cannabidiol and dronabinol, the pharmaceutical form of delta-9-tetrahydrocannabinol. Developed by Beckley Canopy Therapeutics for cancer-associated pain in patients receiving opioid standard of care, it was evaluated against placebo in a randomized, double-blind Phase 1/2 study in Poland. The product is intended to modulate endocannabinoid signaling, principally through cannabinoid receptors 1 and 2; delta-9-tetrahydrocannabinol is the direct cannabinoid receptor agonist component, while cannabidiol has broader modulatory pharmacology. The registered EU trial is listed as completed, with no marketed brand name or regulatory approval identified. ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001382-32/PL))

Other names

CBD + THCcannabidiol + delta-9-tetrahydrocannabinolcannabidiol + dronabinol